The recent discovery describing how OTUB1 control RAS activity (Baietti et al., 2016) may lead to the development of OTUB1 inhibitors targeting RAS mutation based cancers such as pancreatic cancer, colon and melanoma. This evidence concerns the gene OTUB1 and melanoma.